SynthesisEuropean journal of physical and rehabilitation medicine2026
Botulinum toxin in peripheral facial paralysis: systematic review and rehabilitation perspectives.
Synthesis in European journal of physical and rehabilitation medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeripheral facial paralysis (PFP) causes both static and dynamic facial dysfunctions, leading to synkinesis, hypertonia, and aesthetic asymmetry that significantly affect quality of life. Botulinum toxin type A (BTX-A) has become an effective adjunct in rehabilitation, improving facial balance and function. However, there is no consensus regarding optimal injection patterns, dosage, or the therapeutic role of contralateral treatment.
methodsA systematic review of the literature was conducted in accordance with the PRISMA 2020 guidelines. The MEDLINE (PubMed) database was searched for studies published between January 2013 and January 2024 using the terms "Facial Paralysis" AND "Botulinum Toxin." Randomized controlled trials, cohort, and observational studies in English or Spanish analyzing BTX-A treatment in peripheral facial paralysis were included. Data on toxin formulation, injection site, dosage, and outcomes were extracted and qualitatively analyzed.
resultsThirteen studies met the inclusion criteria, encompassing 1821 patients. OnabotulinumtoxinA was the most frequently used formulation. Injections on the affected side were mainly indicated for synkinesis, while contralateral injections aimed to reduce hypertonia and restore facial symmetry. Reported doses ranged from 0.6 to 7.5 U per point. Across studies, BTX-A improved facial symmetry, reduced synkinesis, and enhanced quality of life, with only mild and transient adverse effects.
conclusionsBotulinum toxin is a safe and effective therapeutic tool within the multidisciplinary rehabilitation of peripheral facial paralysis. Despite consistent clinical benefits, heterogeneity in dosing and injection protocols persists. Future randomized studies combining BTX-A therapy with structured neuromuscular rehabilitation are needed to establish standardized evidence-based guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.